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Abstract 
Background: There is emerging evidence that the prevalence of exercise-induced bronchospasm 
(EIB) is significantly under-reported in many sports. There is little known about the potential 
performance improvement that may exist when sports players are detected and treated for EIB. 
Methods: Professional rugby union players with no previous history of asthma volunteered to 
participate in the study. Each player performed the rugby football union (RFU) fitness test and 
completed a eucapnic voluntary hyperpnoea (EVH) challenge at baseline and 12 weeks later. A 
player with a positive EVH result was prescribed beclomethasone inhaler (200 µg; two puffs per day) 
for 12 weeks. Players with a negative EVH test were randomly allocated to either a placebo inhaler 
group or acted as controls. Results: Twenty-nine rugby union players (mean ± SD; age 22.1± 4.2 
years; body mass 100.1± 6.9 kg; height 1.84± 0.07 m) were recruited. Seven players (24% of total) 
had a positive EVH challenge with a mean decrease in FEV1 of -13.6 ±3.5 % from baseline. There 
was no significant group difference (P=0.359) in performance improvement of the RFU fitness test 
EHWZHHQWKH(9+SRVLWLYHJURXSPHDQǻ-22.3 seconds; 8.0 ± 2.8% improvement), placebo group 
PHDQǻ-16.5 seconds; 6.7 ± 1.6% improvement), and FRQWUROVPHDQǻ-12.2 seconds; 5.7 ± 3.5% 
improvement). Conclusion: Prevalence of EIB in professional rugby union players was 24%. A 12-
week prescription of beclomethasone (200 µg) showed similar improvements in RFU fitness test 
performance in players diagnosed with EIB compared to players with healthy airway responsiveness.  
Keywords: screening; asthma, exercise-induced bronchoconstriction; athletic performance 
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Exercise-induced bronchoconstriction (EIB) is 
closely related to asthma and is defined as a 
transient narrowing of the airways, limiting 
expiration that usually follows a bout of 
exercise, and is reversible spontaneously or 
WKURXJKLQKDODWLRQRIȕ2-agonists1. Emerging 
evidence has demonstrated that susceptible 
athletes do not recognise that they have 
EIB2,5. Without the intervention of screening 
programmes, athletes may remain 
undiagnosed and may continue to suffer from 
EIB potentially compromising performance and 
health5,6. The risk of acute bronchoconstriction 
in athletes can be reduced through early 
detection of EIB and suitable treatment7. 
Diagnosis of EIB should incorporate a medical 
consultation and an indirect airway challenge. 
The inclusion of an indirect airway challenge is 
crucial as diagnosing EIB through symptoms 
alone can result in a higher prevalence of false 
positives8,9. The eucapnic voluntary 
hyperpnoea (EVH) indirect airway challenge 
has a high level of sensitivity and specificity for 
the identification of EIB10, and is a suitable 
airway challenge in athletic populations4. 
The proposed mechanism for the development 
of EIB is a dehydration of the airway surface 
liquid caused by the inhalation of large 
YROXPHVRIµXQFRQGLWLRQHG¶DLUUHTXLULQJ
humidification by the lower airways. The 
dehydration of the alveolar surfactant causes 
an osmotic effect that leads to an inflammatory 
response causing bronchoconstriction11. It is 
possible that if the inflammatory process is not 
controlled it may lead to damage of the 
epithelium and resultant airway remodelling. 
Hence sports that have high minute ventilation 
demands and take place in cold, dry 
environments are at risk of airway damage and 
EIB development. It is crucial therefore that 
EIB is detected as early as possible in order to 
control airway inflammation and minimise the 
potential for airway remodelling. Rugby union 
is a sport that requires bouts of high minute 
ventilation and can take place in cold and dry 
environments. Therefore players can put 
themselves at increased risk of EIB and EIB 
development through training and game play. 
The dry environments encountered either at 
cold temperatures or at altitude accompanied 
by high minute ventilation requirements could 
increase the risk of an acute episode of EIB in 
susceptible rugby players12. Despite a number 
of studies reporting a high prevalence of EIB in 
athletes whose sports take place in cold 
environments3,12, there is limited data available 
investigating the prevalence of EIB in rugby 
union players.  
Once diagnosis of EIB has been made the 
most appropriate prevention strategy has been 
shown to incorporate regular use of inhaled 
corticosteroids13-15. However, it is unclear 
whether detection of athletes with previously 
undiagnosed EIB and appropriately treating 
them with inhaled corticosteroid therapy 
results in an improvement in health and 
performance16. At present there are no studies 
that have investigated the longer-term impact 
on health and performance of treating athletes 
with an initial diagnosis of EIB. Accordingly the 
aim of this study is two-fold: 1) to investigate 
the prevalence of undiagnosed EIB in rugby 
union players; 2) investigate the impact of 
corticosteroid therapy on airway function of 
susceptible rugby union players and how this 
impacts on a rugby-specific performance test.   
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Twenty-nine professional male rugby players 
from the same club in Northern England were 
approached to participate in the study. All 
participants agreeing to participate in the study 
provided written informed consent and ethical 
approval was provided by Leeds Metropolitan 
University. All tests were performed during 
pre-season training. Inclusion and exclusion 
criteria for the study are outlined in Table 1.  




Member of the same rugby union club  Recent chest infection (less than four weeks 
prior to testing) 
Male A current diagnosis of asthma and/or EIB and 
using inhaler therapy. 
Age: 18-30 years FEV1 of <70% predicted value at baseline 
spirometry. 
 Participants with injuries which will prevent 
them from completing maximal fitness testing 
 
 
The Rugby Football Union (RFU) fitness 
test 
The RFU fitness test17 was conducted on all 
participants (Figure 1). The test was familiar 
and was conducted regularly as part of routine 
training and fitness assessments. The RFU 
fitness test is similar to the 20 m multi-stage 
fitness test18, involving a number of timed 
repeated sprints. There are two different RFU 
fitness tests dependent on whether the player 
is a forward or back, and participants 
completed the test according to their playing 
position.  
 
Figure 1: The RFU fitness test for forwards (left panel) and backs (right panel) 
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All participants performed an EVH challenge 
within the same week as the fitness test. 
Maximal flow volume loops were recorded 
using a digital spirometer (ML3500 Micro 
Medical Spirometer, Cardinal Health, UK). The 
European Community for Coal and Steel 
(ECCS) reference values were used to predict 
maximal lung flow-volumes19. All maximal flow-
volume manoeuvres were performed in 
accordance with the European Respiratory 
Society criteria20. Prior to the EVH challenge 
participants completed three maximal flow-
volume manoeuvres. The best FEV1 was 
recorded and taken as baseline lung function. 
Other measurements collected included forced 
vital capacity (FVC), peak expiratory flow 
(PEF), and mid-expiratory flow rate at 50% of 
FVC (FEF50). 
The EVH challenge was carried out in 
accordance with methods outlined by 
Anderson et al.21. During the EVH challenge 
each participant was asked to achieve target 
minute ventilation ( E) of 85% of the maximal 
voluntary ventilation (MVV) for six minutes. 
Target E was calculated by multiplying the 
baseline FEV1 by 3021. The gas inhaled during 
the EVH challenge consisted of 74% nitrogen, 
21% oxygen, and 5% carbon dioxide. At the 
point of air entering the mouth the gas 
temperature was 18ͼ C and humidity <2%. 
During the EVH challenge verbal 
encouragement and visual feedback was 
provided. Upon completion of the EVH 
challenge, two maximal flow- volume loops 
were recorded at 3, 5, 7, 10 and 15 minutes 
respectively. At each time point the flow-
volume loop with the best FEV1 was recorded 
and used to calculate the decrease from the 
baseline FEV1 at each time point. If FEV1 was 
>10% from baseline at two consecutive time 
points this was deemed a positive EVH 
challenge. If participants presented with two 
consecutive time points where FEV1 fell >10% IURPEDVHOLQHWKH\ZHUHRIIHUHGȝJRI
inhaled salbutamol and a repeat flow-volume 
loop was measured 10 minutes after 
inhalation. All participants were asked to 
remain in the laboratory until their FEV1 was 
within 10% of the baseline measure. 
Participants were diagnosed with EIB if:  
 They had a fall in FEV1 >10% from 
baseline at two consecutive time 
points following the EVH challenge.  
 The participant had an initial low-
normal FEV1 (70-80% of predicted 
value at baseline spirometry with 
persistent respiratory symptoms. 
Following the EVH challenge there 
was a minimal decrease in the 
percentage of the FEV1, yet following 
use of a salbutamol inhaler there was 
an improvement of >12% from the 
baseline FEV1. 
 Each decision about a participant 
being diagnosed with EIB was taken in 
FRQVXOWDWLRQZLWKWKHFOXE¶VWHDP
doctor.  
A participant was deemed to be EVH negative 
if the FEV1 did not demonstrate a drop of ൒10% on two consecutive time points.  
Randomisation of participants 
Players were all blinded to the results and 
were also blinded as to whether they received 
a placebo or beclomethasone inhaler. All 
players diagnosed with EIB were prescribed 
beclomethasone inhaler 200µg (two puffs per 
day). The negative EVH group was randomly 
selected to either receive a placebo inhaler to 
be used twice daily or they formed part of the 
control group that received no treatment. Both 
groups were shown how to use the inhaler by 
the club doctor and were sent a daily reminder 
to use their inhaler, to ensure compliance. All 
participants completed their regular pre-
season exercise training regimens. After 
twelve weeks, all players underwent re-
assessment of the RFU fitness test under 
identical conditions. The EVH challenge was 
repeated in players with a positive diagnosis 
for EIB. 
Data analysis 
Continuous variables are presented as mean 
and standard deviation (SD); categorical 
variables are reported as percentages. A one-
way analysis of variance (ANOVA) was used 
to identify baseline differences between 
groups. A repeated measures ANOVA with 
Bonferroni post hoc adjustment was used to 
identify differences over time (baseline to 12 
weeks). An arbitrary level of 5% statistical 
significance (two-tailed) was assumed. SPSS 
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software v17.0 (IBM, NY, USA) was used to analyse the data.   
Results 
Twenty-nine professional rugby union players 
(mean ± SD; age 22.1 ± 4.1 years; height 
1.84 ± 0.07 m, body mass 100.1 ± 12.3 kg) 
agreed to participate in the study. There were 
no baseline differences in age, height, and 
body mass between players with positive and 
negative EVH results (Table 2). The baseline 
RFU fitness test was completed by 24 
participants; whilst 5 did not participate/did not 
complete it. However, due to injury and/or 
illness, only 16 participants completed both the 
baseline and 12-week post intervention RFU 
fitness tests.  
Table 2: Player characteristics separated by positive and negative EVH results at baseline 
Characteristic EVH positive (n=7) EVH negative (n=22) p-value 
Age (years) 22.6 ± 3.8 22.0 ± 4.4 0.887 
Height (m) 1.87 ± 6.3 1.83 ±7.0 0.189 
Weight (kg) 101.9 ± 11.2 99.6 ±12.8 0.713 
FEV1 (l) 4.5±0.7 5.0±0.7 0.76 
Percent of predicted 
FEV1 
94.3±11.1 109.0±11.0 0.01 
FVC (l) 5.8±0.9 6.0±0.9 0.670 
PEF (l/min) 601.9± 69.8 640.7± 88.3 0.299 
FEF50 (l/min) 4.3 ±0.8 5.8±1.4 0.017 
Max FEV1 decrease post 
EVH challenge 
-11.6 ± 4.6 -6.0±3.6 0.002 
 
None of the 29 participants had a previous 
diagnosis of asthma or EIB. Seven players 
(24%) were diagnosed with EIB. Of these, five 
had a positive EVH challenge and two 
presented with significant reversibility following 
inhalation of salbutamol. Three other 
participants demonstrated a fall in FEV1 of 
>10%, but only at one time point. There was 
no significant difference in the baseline 
maximal flow volume measures between 
players with positive and negative EVH 
challenges. However, the baseline percentage 
of predicted FEV1 and the FEF50 was 
significantly higher in the players with negative 
results (P=0.01, P =0.017 respectively). Seven 
participants (24%) were diagnosed with EIB. 
The maximal decrease in FEV1 was 
significantly (P=0.002) higher in the EVH 
positive group (Table 2). There was no 
significant relationship between the 
percentage of MVV achieved and the 
maximum FEV1 fall post EVH challenge 
(P=0.74) (Figure 2). Figure 3 illustrates the 
individual percentage decrease in FEV1 in 
players with positive and negative responses.  
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Figure 2: Percentage of MVV achieved during the EVH challenge and the percentage decrease in 
FEV1 from baseline following the EVH challenge 
 
 
Figure 3: Changes in FEV1 in rugby union players with positive and negative responses to the EVH 
challenge 
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RFU Fitness Test 
Sixteen out of twenty-four players completed 
the baseline and 12 week follow up RFU 
fitness test. Seven players were found to be 
EIB positive. All three groups, EIB positive, 
placebo and control improved their fitness test 
scores after 12 weeks of training 
(P=0.014).When taken on an individual basis, 
all participants improved their RFU fitness test 
performance times over the 12-week period. 
There was no significant group difference 
(P=0.359) in performance improvement of the 
RFU fitness test between the EVH positive 
JURXSPHDQǻ-22.3 seconds; 8.0 ± 2.8% 
LPSURYHPHQWFRQWUROVPHDQǻ-12.2 
seconds; 5.7 ± 3.5% improvement), and the 
SODFHERJURXSPHDQǻVHFRQGV± 
1.6% improvement) (Figure 4). A second EVH 
test was repeated after 12 weeks in players 
with an initial diagnosis of EIB. A decrease in 
FEV1 of >10% continued to remain in all 
players following the treatment period. 
 
 
Figure 4: Comparison of the mean time taken to complete the RFU fitness test at baseline and after 
the 12-week intervention for player5s with a positive EVH, placebo group, and controls 
 
Discussion 
This is the first study to screen a team of rugby 
union players for EIB and track changes in 
performance in those detected with EIB with 
no previous diagnosis. This study shows that 
the prevalence of EIB in rugby union players 
with no previous history of asthma is 24%. 
Following 12-week inhalation of prescribed 
beclomethasone (200µg), the EIB group 
showed significant improvement in the RFU 
fitness test. Although the EIB positive group 
significantly improved their RFU fitness 
performance from baseline they did not 
improve at a significantly greater rate than the 
placebo group or controls. The EIB group 
demonstrated the greatest fitness 
improvement over the intervention and this 
VWXG\¶V findings are similar to previous data 
from asthmatics recruited to a six-week 
treatment programme with inhaled 
corticosteroids22. The improvement in fitness 
was seen across all groups is due to the 
testing being held during the pre-season 
training, where the players are in the building 
up fitness phase after a short layoff from 
training. 
The high airway resistance that occurs during 
EIB increases the expiratory flow limitation 
Exercise-induced bronchoconstriction in rugby players International SportMed Journal, Vol.15 No.4, December 2014,  
pp. 333-342. Available at URL: http://www.ismj.com 
 
340 Official Journal of FIMS (International Federation of Sports Medicine) 
 
during exercise23 predisposing athletes to 
hypoxaemia during exercise.  Haverkamp et 
al.24 found a significant decrease in arterial 
oxygen saturation during exercise caused by 
an increased difference in alveolar to arterial 
PO2 pressure and an insufficient ventilatory 
response resulting in reduced exercise 
performance. Six weeks of inhaled 
corticosteroids increased arterial blood oxygen 
saturation during exercise and exercise 
performance in asthmatics24. It is hypothesised 
that if these authors had not treated the EIB 
group they may have had impaired adaptation 
in fitness over the 12 weeks of training. Due to 
ethical issues surrounding not treating an 
athlete for EIB, once a diagnosis has been 
made these authors were unable to test this 
hypothesis in their study. The EVH challenge 
identified 24% of rugby union players with 
underlying EIB. This is similar to previous 
findings by Dickinson et al.5 where 32% of 
rugby players were found to have undiagnosed 
EIB5. There is the potential for EIB to develop 
in an athlete following over exposure during 
training and competition to high ventilatory 
demands, dry air, or poor air quality12,25,26 . It 
may take several years of exposure to a 
provocative environment for EIB to develop in 
susceptible individuals27. 7KLVVWXG\¶V group of 
rugby players were relatively young (mean age 
22.6 years), and it is feasible that in an older 
group of players the number of positive tests 
may have been greater, providing similar 
findings to Dickinson and colleagues 5. 
These authors found that the maximal flow-
volume measures at baseline did not 
distinguish between players with positive and 
negative results. FEV1 is commonly used to 
help diagnose intrinsic asthma, as it measures 
the expiratory flow at high and mid-lung 
volumes. The baseline FEV1 was within the 
normal range for all participants (>80% of the 
predicted FEV1), hence identification of 
undiagnosed EIB through analysis of the 
resting FEV1 (pre-exercise) was not possible. 
This is supported by previous findings4,5. The 
exception to this is the % predicted FEV1 
obtained at baseline. Players with a positive 
diagnosis of EIB had significantly lower 
(P=0.011) % predicted FEV1 values compared 
to healthy controls at baseline. This result is 
similar to studies conducted on large cohorts 
of elite athletes that report EIB athletes to have 
significant lower % of predicted FEV1 
measures4,5. It is difficult to distinguish players 
with a positive EVH test by analysis of the % 
predicted FEV1 as values are still within the 
normal range (>80% predicted value). Beck 
and colleagues28 demonstrated that baseline 
spirometry in an athletic population was >20% 
higher than the predicted values for the 
general population. Future studies should 
GHWHUPLQHDQDGMXVWHGµQRUPDOUDQJH¶IRUKLJK
performance athletes (which may require 
further sub-specialisation for sporting mode i.e. 
power vs endurance sports). 
In this study, the players diagnosed with EIB 
were treated with inhaled corticosteroids as 
per the British Thoracic Society Guidelines29, 
with inhaled beclomethasone, as this was 
found to improve EIB22. The option of providing 
WKH(,%SRVLWLYHSDUWLFLSDQWVZLWKVROHO\ȕ2-
agonists was nRWIHDVLEOHDVDOWKRXJKȕ2-
agonists can inhibit mast cell mediator release, 
this response is susceptible to desensitisation, 
a process that can be inhibited by 
corticosteroids. Corticosteroids can increase 
WKHWUDQVFULSWLRQRIWKHȕ2-receptor gene in the 
lung and the nasal mucosa. This effect of 
corticosteroids lessens the reduction in 
WUDQVFULSWLRQRIWKHȕ2-receptors, which would RFFXUDVDUHVXOWRIORQJWHUPȕ2-agonist 
administration30. However, when players with 
positive results for EIB underwent a repeated 
EVH challenge after 12 weeks of treatment, all 
participants still demonstrated a decrease in 
FEV1 >10%. Thus, other treatment options 
including fluticasone30 or leukotrienes may 
require further consideration, although the 
latter is not considered a first-line treatment for 
EIB32.  
 
There does not appear to be a relationship 
between respiratory symptoms and the 
presence/absence of EIB. Rundell and co-
workers3 showed that in athletes experiencing 
a decrease of ൒10% in FEV1 post-exercise 
challenge, respiratory symptoms were 
reported by 39% of athletes. Conversely, in 
athletes with EIB, respiratory symptoms were 
reported by 41%. These authors found a 
similar trend in their study; 76% of the rugby 
players without EIB experienced respiratory 
symptoms, whilst 71% of the players with EIB 
denied any respiratory symptoms. This finding 
adds weight to previous studies which 
indicates that the analysis of signs and 
symptoms are not a reliable method of 
diagnosing or rejecting EIB3. Thus the 
diagnosis of EIB must include an objective test 




This study¶V cohort presented with mild 
bronchoconstriction following the EVH 
challenge (decrease in FEV1 from baseline 
between 10-25%). The authors may have seen 
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larger performance gains by using a group of 
athletes with moderate to severe EIB. In 
addition, the field-based assessment (RFU 
fitness test) whilst being ecologically valid and 
familiar to the rugby players, was less well-
controlled than a laboratory testing 
environment.  The EVH challenge is a highly 
sensitive and specific test for the diagnosis of 
underlying EIB4. However the humidity of the 
air (2%) is much lower than any athlete is likely 
to inhale during most sporting situations. 
Occasionally, this may lead to over-cautious 
diagnosis of EIB where the impact of inhaled 
medication may be less significant.   
 
Conclusion 
Prevalence of EIB in professional rugby union 
players was 24%. A 12-week prescription of 
beclomethasone (200 µg) showed similar 
improvements in RFU fitness test performance 
in players diagnosed with EIB compared to 
players with healthy airway responsiveness.   
 
What is already known? 
x Athletes are susceptible to EIB 
x Screening athletes with an indirect 
airway challenge such as EVH testing 
may result in diagnosis of EIB in 
previously undiagnosed athletes 
 
What are the new findings?  
x The prevalence of EIB in UK-based 
rugby union players was 24% 
x Diagnosing EIB in rugby union players 
with no previous history and treating 
them with inhaled corticosteroids for 
12 weeks allows them to make similar 
performance gains as players with 
healthy airway responsiveness. 
 
How might it impact on clinical practice in the 
future? 
x Increased testing for undiagnosed EIB 
in high-performance athletes. This will 
aid to protect airway health and to 
allow these athletes to perform at their 
optimal level whilst remaining healthy. 
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